



Studying Nocturnal Blood Pressure Patterns and Levels and Obstructive Sleep Apnea: Clinical Implications and Technical Solution

Hong Lien Nguyen Thi, Khuyen Pham Thi, Bich Hue Bui Thi,
Thu Hang Tran Thi, Minh Thu Vu Thi, Khai Nguyen Van and
Linh Pham Van

EasyChair preprints are intended for rapid
dissemination of research results and are
integrated with the rest of EasyChair.

June 3, 2020

Studying nocturnal blood pressure patterns and levels and obstructive sleep apnea: Clinical implications and technical solution

Nguyen Thi Hong Lien^{1,2}, Pham Thi Khuyen^{1,2}, Bui Thi Bich Hue², Tran Thi Thu Hang¹, Vu Thi Minh Thu⁴, Nguyen Van Khai³, Pham Van Linh^{1,2}[0000-0001-7107-1496]

¹Pathophysiology-Clinical Immunology Dept, Haiphong University of Medicine and Pharmacy

²Cardiovascular Medicine & Pulmonology, Haiphong University Hospital

³Specialized Physician & Senior Manager, Haiphong University Hospital

⁴Senior Nursing and Social Work Officer, Viet-Tiep Friendship Hospital

Corresponding address: pvlinh@hpmu.edu.vn

Abstract.*Background:* Beside specific consequences, obstructive sleep apnea (OSA) has been described as a novel and major risk factor of high blood pressure (BP), cardiovascular complications and organ damage. Ambulatory blood pressure monitoring (ABPM) is now considered as part of standard of care in management of hypertension. The study aims to initially describe possible association between BP levels and patterns, especially nighttime BP, and OSA.

Methodology: The study was conducted on both inpatient and outpatient subjects who have clear or dim notion of fluctuating clinical or self-measured home BP. Cardiorespiratory polygraphy indicated, when appropriate, led to the identification of two subgroups (with or without OSA). The 24-hour ABPM was then indicated to perform on subjects of both subgroups. Both exploratory techniques are non-invasive and have their own indication in clinical contexts.

Results: In two subgroup of 12 and 19 patients with or without OSA respectively, ABPM reported initially a higher proportion of isolated nocturnal hypertension, non-dipper nocturnal BP patterns or nighttime BP surges in subgroup of patients with OSA compared that recorded in non-OSA control subgroup.

Conclusion and Discussion: Initial study results suggest the patterns of nocturnal BP in patients with- and without OSA. Nocturnal BP level and pattern, which could only be achieved for now by ABPM holter systems, appear to have increasing importance and link to OSA. Clinical implications issue of high nocturnal BP may set needs for technical works of combination that enables simultaneous analyses of both patient's nocturnal BP and sleeping state.

Keywords: Nocturnal BP, non-dipping BP, OSA, integrating technical work

1 Background

In the context of increasing non-communicable chronic diseases related to environmental pollution and unhealthy habits, in addition to diabetes, chronic lung disease and cancer, cardiovascular diseases and related pathologies are rising as the main disease group with high disease burden and mortality. Some diseases such as hypertension, diabetes, lipid disorders on one hand are pathologies have their own risk factors, they are on their turn considered as risk factors for a chain of diseases. Cardiovascular disease can lead to ultimate consequences of heart failure, major cardiovascular events and death.

In addition to paying attention to primary risks, attention paid to secondary risk factors by proper awareness, management and good treatment of conditions such as hypertension, diabetes, blood lipid disorders, overweight/obesity serves not only to these specific conditions but also have important effects for preventable secondary events.

Hypertension (or high BP) is defined with defining levels of blood pressure which were varied a little bit according to office/clinic, ambulatory or home BP measurement, and to major professional societies. Hypertension is a common medical condition, easy to diagnose, having effective interventions and treatment, but there still remain many challenges. The first challenge for hypertension comes from the condition itself, the number of sufferers, its rising trend, the heavy consequences and dangerous complications of hypertension, the low rate of diagnosis (roughly only one out two), treated and controlled rates are also low (roughly only one out ten). [1-4] Besides cardiovascular risks, hypertension has also been identified as the most common risk factor for chronic kidney disease.[5] The mortality rate associated with hypertension increases exponentially with the increase in blood pressure levels in hypertensive patients.[6,7] This fact increases the challenge when placed alongside with evidence of a very clear effect of treatment and tighter control of blood pressure reduces mortality by cardiovascular events such as stroke, ischemic heart diseases [6,8-10], when the key points in the recommendations for diagnosis, treatment and management of hypertension, built from research evidence, are reaching agreement.[11,12] There is still the critical problems associated with ambulatory blood pressure measurement, nocturnal hypertension and masked hypertension[13-15]

The current indications of polysomnography or cardiorespiratory/respiratory polygraphy are focused on a number of clinical features that are often associated with obstructive sleep apnea syndrome (OSA, OSAS). However, the combination of obstructive sleep apnea and hypertension suggest an appropriate practical attitude is to prescribe this exploratory examination for diagnosed or suspected hypertension and in the reverse direction, ambulatory blood pressure monitoring by a holter system is indicated in case the OSAS was identified. Drager's research showed that the presence of metabolic syndrome (MetS) is a more important hint over suggestive signs of obstructive sleep apnea. [16]

In hypertension, a number of issues have been being reconsidered, from the most basic issues such as determining the threshold values for determining hypertension (systolic blood pressure repeated consistently at ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg with blood pressure measured in hospitals (clinic/office BP), the use of automated measuring devices at hospitals, clinics and ambulatory, at home. As of 2013, blood pressure measurements at clinics or hospitals are considered as the standard for screening, diagnosis, and follow-up of treatment for hypertension. However, measurement of blood pressure at a clinic or hospital does not generally allow the identification of white-coat hypertension, masked hypertension or nocturnal hypertension, nor can it help to determine with certainty whether the treatment currently being applied in the patient provides good blood pressure control. [17,18] Since evidence confirms that recording blood pressure at a hospital or clinic is not a highly reliable method, the diagnosis of hypertension requires blood pressure readings to be reconfirmed, preferably with blood pressure measured outside clinic or hospital, at home or ambulatory. Standardized electronic blood pressure devices that automatically perform 3 measurements and calculate the average results are recommended

for use (should be preferred than traditional devices) in clinical practice.[19,20] At the same time, the measurement and recording with out-of-hospital ambulatory mobile blood pressure (self-measurement and home-based recording are formally recommended to perform in priority in confirming the diagnosis of hypertension as well as in titrate of medication treatment for appropriate dose in clinical practice as well as in providing a reliable basis for remote treatment counseling. [12] Ambulatory blood pressure monitoring is recommended and encouraged to used widely for all patients requiring hypertension screening or in diagnostic purpose; considered in a reasonable exploratory examination, which should be paid for (by Health Insurance) in the management of hypertension. Diagnosis of hypertension through ambulatory or home BP recording is based on lower blood pressure thresholds (130/80 mmHg for outpatient ambulatory blood pressure recording and 135/85 mmHg for home blood pressure monitoring). Monitoring of blood pressure at home has also been found to be beneficial in improving attention, accountability, and, as a result, blood pressure control rates. [21] In addition to helping to determine the diagnosis of hypertension reliably, blood pressure levels in patients also help determine the overall cardiovascular risk level.

Obstructive sleep apnea (OSA) and hypertension have a special link where OSA have been described and suggested, in both observational and prospective studies, as a novel and major risk factor of high blood pressure.[22-24] This study was carried out to explore the potential link between OSA and masked hypertension with its clinically relevant BP variability patterns.

Methodology

The study was conducted on both inpatient and outpatient subjects who have vague notion of fluctuating clinical or self-measured home BP. Respiratory polygraphy indicated, when appropriate (cases of presumed arterial hypertension), led to the identification of two subgroups (with or without OSA). The 24-hour ABPM was then indicated to perform on subjects of both subgroups. The obstructive sleep apnea was diagnosed using Philips Respironics Alice NightOne device and its software. [25] The patient's 24-hour blood pressure was measured and recorded by ASPEL HolCARD CR-07 Ambulatory Blood Pressure System, analysed with HolCARD CR-07 software.[26] Both exploratory techniques are non-invasive and have their own indication in clinical contexts. The diagnosis of obstructive sleep apnea (OSA) was made by ambulatory or in-hospital seven-channel cardio-respiratory polygraphy using reliable and easy-to-use home sleep testing Alice NightOne device. 'Manual' scoring analysis was assisted by the native Alice software. An AHI of less than 5 (events per hour) is considered normal (non-OSA). OSA with AHI ≥ 5 and < 15 is classified as mild; AHI ≥ 15 and < 30 as moderate and an AHI more than 30 characterizes severe OSA.[27]

Thresholds or cut-off values used for the definition of hypertensive entities were 130/80 mmHg for 24-h ABPM (≥ 130 mm Hg systolic or 80 mm Hg diastolic), 135/85 mmHg for daytime ABPM and home BP, 120/70 mmHg for night-time BP. Isolated nocturnal hypertension was defined as a night-time blood pressure of $\geq 120/70$ mm Hg and a daytime blood pressure $< 135/85$ mm Hg; isolated daytime hypertension as a daytime blood pressure of $\geq 135/85$ mm Hg and a nighttime blood pressure $< 120/70$ mm Hg; sustained hypertension as a nighttime blood pressure of $\geq 120/70$ mm Hg and a

daytime blood pressure of $\geq 135/85$ mm Hg. Ambulatory normotension is defined as a nighttime blood pressure $< 120/70$ mm Hg and a daytime blood pressure $< 135/85$ mm Hg.[11,13,17,18]The BP dipping patterns, which were determined by systolic nighttime to daytime BP ratio. Non-dipping pattern (or reduced nighttime dip) is described as the ratio $> 0,9$; the ratio > 1 will be described as reverse-dipping pattern.

Results

The essential patient's characteristics of two study subgroups were presented in *Table 1*.The patients of two study groups differ in some key anthropometric parameters, namely BMI, waist circumference (WC) and the WC-to-height ratio (WHtR).

Although patients enrolled in this study have a vague notion of hypertension, neither of them had documentedly diagnosed or were currently treated. The confirmation of systemic hypertension by ABPM helped diagnose the masked hypertension in 10 (out of 12), and in 11(out of 19) in patients with- and without OSA respectively. The study also characterized, among those with masked hypertension (demasked and confirmed by ABPM), some nocturnal BP patterns, including nocturnal hypertension, non-dipping nocturnal BP and night-time reverse-dipping, and revealed initially a higher proportion of these patterns in subgroup of patients with OSA compared to that recorded in non-OSA control subgroup.

Table 1. Characteristics of patients in two subsets.

Patient's characteristics		OSA (+)(12)	OSA (-)(19)	p
Demographic	Age (rang)	61,5 (47-78)	64,7 (34-84)	
	Malegender (%)	10 (83,3)	9 (47,4)	0.0493
Anthropometric	BMI (kg/m ²)	30,1	24,0	<0.0001
	WC (cm)	109,25	87,9	<0.0001
	WHtR	0,67	0,55	<0.0001
	AHI (events/h)	17,8	1,8	
24-H ABPM	sBP (mmHg)	136,5	133,3	0.4322
	dBP (mmHg)	81,3	79,7	
Nocturnal ABPM	sBP (mmHg)	130,6	121,8	0.0367
	dBP (mmHg)	75,1	69,7	
Diurnal ABPM	sBP (mmHg)	140,4	140,2	0.3060
	dBP (mmHg)	88,9	85,2	
Dipping pattern	sBP N/D	0,96	0,87	0,0127

AHI: Apnea-hypopnea index; sBP: systolic BP; dBP: diastolic BP; N/D: Daytime to nighttime sBP ratio

Discussions

This study is directed to indicate the cardiorespiratory polygraphy in patients with suspected hypertension, and, in return, to redetermine the blood pressure status, via 24-hour ambulatory blood pressure monitoring in two sub-classified groups of patients (with and without obstructive sleep apnea). The study results continue to suggest a combination of OSA and hypertension. Although large studies have identified a causal relationship in which obstructive sleep apnea has been identified as a secondary cause of hypertension and is associated with resistant hypertension, [22,28], the relationship between OSA and hypertension continues to require epidemiological studies analyzing pathogenesis, identifying real underlying risk factors for more meaningful preventive interventions. A prospective follow-up study of middle-aged and elderly patients with OSAS without hypertension shows the important role of overweight/obesity in the formation of hypertension. as well as the predictive significance of nocturnal BP abnormalities [17,29]

In current study, nocturnal blood pressure abnormalities were not identified due to the intrinsic blood pressure abnormality in the patient or to influence of automatic blood pressure measurement during the night that have affected sleep and thereby affecting blood pressure (patient which awakened and got stressed). A valuable technical solution might be integration of BP measuring module in to polygraph device (or in reverse direction).

A prospective descriptive study found that patient' BP readings during the night were correlated with patient's subjective assessment of decrease in sleep time associated with blood pressure recording being performed automatically during the night; at the same time, the prognostic value of nocturnal blood pressure for cardiovascular outcomes and overall mortality (all causes) is lost in patients who experience a markedly reduced (≥ 2 hours) of sleep time during the night[30]

Whether hypertension or masked hypertension, nocturnal hypertension or nocturnal BP surges or reduced nighttime BP dip (non-dipping or reverse-dipping patterns) are associated with OSA, with sleep shortening or reduced sleep quality or insomnia, and these conditions are related or independent of overweight or obesity (including normal weight obesity, NWO), cardiorespiratory polygraph indicated and performed on those with hypertension or suspected abnormal of BP do have beneficial value especially when the test is performed simultaneously with blood pressure monitoring. [17,18,22,31,32] This again suggests strongly a technical solution in which the blood pressure monitoring is integrated into the central processing module of cardiorespiratory polygraph.

At present, the diagnosis of arterial hypertension makes use either repeated visits for office BP measurement or out-of-office measurement. The ABPM could be indicated as adjunct to office BP monitoring and HBPM in cases of suspect or masked hypertension, and to assess the nighttime BP. Along with office/clinic BP measurement and home blood pressure monitoring (HBPM), the ambulatory blood pressure monitoring (ABPM) by allowing assessment of nighttime BP, short-term BP variability provides an additive and stronger tool for diagnosis, prognosis and the follow-up. The close cooperation between clinical and BME teams might help elaborate technical projects to develop or improve the currently used devices.

Reference

- [1] P. T. Son, N. N. Quang, N. L. Viet, P. G. Khai, S. Wall, L. Weinehall, R. Bonita, and P. Byass, Prevalence, awareness, treatment and control of hypertension in Vietnam—results from a national survey, *J. Hum. Hypertens.*, 26 (2012) 268-280.
- [2] P. M. Kearney, M. Whelton, K. Reynolds, P. Muntner, P. K. Whelton, and J. He, Global burden of hypertension: analysis of worldwide data, *Lancet*, 365 (2005) 217-223.
- [3] H. T. Do, J. M. Geleijnse, M. B. Le, F. J. Kok, and E. J. Feskens, National prevalence and associated risk factors of hypertension and prehypertension among Vietnamese adults, *Am. J. Hypertens.*, 28 (2015) 89-97.
- [4] C. K. Chow, K. K. Teo, S. Rangarajan, S. Islam, R. Gupta, A. Avezum, A. Bahonar, J. Chifamba, G. Dagenais, R. Diaz, K. Kazmi, F. Lanas, L. Wei, P. Lopez-Jaramillo, L. Fanghong, N. H. Ismail, T. Puoane, A. Rosengren, A. Szuba, A. Temizhan, A. Wielgosz, R. Yusuf, A. Yusufali, M. McKee, L. Liu, P. Mony, and S. Yusuf, Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries, *JAMA*, 310 (2013) 959-968.
- [5] A. K. Singh, Y. M. Farag, B. V. Mittal, K. K. Subramanian, S. R. Reddy, V. N. Acharya, A. F. Almeida, A. Channakeshavamurthy, H. S. Ballal, P. G. R. Issacs, S. Jasuja, A. L. Kirpalani, V. Kher, G. K. Modi, G. Nainan, J. Prakash, D. S. Rana, R. Sreedhara, D. K. Sinha, V. SB, S. Sunder, R. K. Sharma, S. Seetharam, T. R. Raju, and M. M. Rajapurkar, Epidemiology and risk factors of chronic kidney disease in India - results from the SEEK (Screening and Early Evaluation of Kidney Disease) study, *BMC. Nephrol.*, 14 (2013) 114.
- [6] S. Lewington, R. Clarke, N. Qizilbash, R. Peto, and R. Collins, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, *Lancet*, 360 (2002) 1903-1913.
- [7] A. V. Chobanian, G. L. Bakris, H. R. Black, W. C. Cushman, L. A. Green, J. L. Izzo, Jr., D. W. Jones, B. J. Materson, S. Oparil, J. T. Wright, Jr., and E. J. Roccella, Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, *Hypertension*, 42 (2003) 1206-1252.
- [8] J. T. Wright, Jr., J. D. Williamson, P. K. Whelton, J. K. Snyder, K. M. Sink, M. V. Rocco, D. M. Reboussin, M. Rahman, S. Oparil, C. E. Lewis, P. L. Kimmel, K. C. Johnson, D. C. Goff, Jr., L. J. Fine, J. A. Cutler, W. C. Cushman, A. K. Cheung, and W. T. Ambrosius, A Randomized Trial of Intensive versus Standard Blood-Pressure Control, *N. Engl. J. Med.*, 373 (2015) 2103-2116.

- [9] A. C. Sousa, T. V. Jardim, T. O. Costa, F. G. Magalhaes, M. P. M. Montelo, W. K. B. Souza, P. C. B. V. Jardim, and A. L. L. Sousa, Hypertensive diabetic patients: incidence of cardiovascular and renal outcomes in a historical cohort over 11 years, *Diabetol. Metab Syndr.*, 9 (2017) 98.
- [10] S. Oparil, M. C. Acelajado, G. L. Bakris, D. R. Berlowitz, R. Cifkova, A. F. Dominiczak, G. Grassi, J. Jordan, N. R. Poulter, A. Rodgers, and P. K. Whelton, Hypertension, *Nat. Rev. Dis. Primers.*, 4 (2018) 18014.
- [11] B. Williams, G. Mancia, W. Spiering, R. E. Agabiti, M. Azizi, M. Burnier, D. L. Clement, A. Coca, S. G. de, A. Dominiczak, T. Kahan, F. Mahfoud, J. Redon, L. Ruilope, A. Zanchetti, M. Kerins, S. E. Kjeldsen, R. Kreutz, S. Laurent, G. Y. H. Lip, R. McManus, K. Narkiewicz, F. Ruschitzka, R. E. Schmieder, E. Shlyakhto, C. Tsioufis, V. Aboyans, and I. Desormais, 2018 ESC/ESH Guidelines for the management of arterial hypertension, *Eur. Heart J.*, 39 (2018) 3021-3104.
- [12] P. K. Whelton, R. M. Carey, W. S. Aronow, D. E. Casey, Jr., K. J. Collins, H. C. Dennison, S. M. DePalma, S. Gidding, K. A. Jamerson, D. W. Jones, E. J. MacLaughlin, P. Muntner, B. Ovbiagele, S. C. Smith, Jr., C. C. Spencer, R. S. Stafford, S. J. Taler, R. J. Thomas, K. A. Williams, Sr., J. D. Williamson, and J. T. Wright, Jr., 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, *Hypertension*, 71 (2018) e13-e115.
- [13] Y. Li and J. G. Wang, Isolated nocturnal hypertension: a disease masked in the dark, *Hypertension*, 61 (2013) 278-283.
- [14] K. Kario, [Masked hypertension--its pathophysiology and treatment], *Nihon Naika Gakkai Zasshi*, 96 (2007) 79-85.
- [15] K. Kario, Nocturnal Hypertension: New Technology and Evidence, *Hypertension*, 71 (2018) 997-1009.
- [16] L. F. Drager, P. R. Genta, R. P. Pedrosa, F. B. Nerbass, C. C. Gonzaga, E. M. Krieger, and G. Lorenzi-Filho, Characteristics and predictors of obstructive sleep apnea in patients with systemic hypertension, *Am. J. Cardiol.*, 105 (2010) 1135-1139.
- [17] G. Parati, G. Stergiou, E. O'Brien, R. Asmar, L. Beilin, G. Bilo, D. Clement, A. de la Sierra, L. P. de, E. Dolan, R. Fagard, J. Graves, G. A. Head, Y. Imai, K. Kario, E. Lurbe, J. M. Mallion, G. Mancia, T. Mengden, M. Myers, G. Ogedegbe, T. Ohkubo, S. Omboni, P. Palatini, J. Redon, L. M. Ruilope, A. Shennan, J. A. Staessen, G. vanMontfrans, P. Verdecchia, B. Waeber, J. Wang, A. Zanchetti, and Y. Zhang, European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring, *J. Hypertens.*, 32 (2014) 1359-1366.

- [18] G. Mancia, R. Fagard, K. Narkiewicz, J. Redon, A. Zanchetti, M. Bohm, T. Christiaens, R. Cifkova, B. G. De, A. Dominiczak, M. Galderisi, D. E. Grobbee, T. Jaarsma, P. Kirchhof, S. E. Kjeldsen, S. Laurent, A. J. Manolis, P. M. Nilsson, L. M. Ruilope, R. E. Schmieder, P. A. Sirnes, P. Sleight, M. Viigimaa, B. Waeber, and F. Zannad, 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), *J. Hypertens.*, 31 (2013) 1281-1357.
- [19] M. Roerecke, J. Kaczorowski, and M. G. Myers, Comparing Automated Office Blood Pressure Readings With Other Methods of Blood Pressure Measurement for Identifying Patients With Possible Hypertension: A Systematic Review and Meta-analysis, *JAMA Intern. Med.*, 179 (2019) 351-362.
- [20] P. Muntner, D. Shimbo, R. M. Carey, J. B. Charleston, T. Gaillard, S. Misra, M. G. Myers, G. Ogedegbe, J. E. Schwartz, R. R. Townsend, E. M. Urbina, A. J. Viera, W. B. White, and J. T. Wright, Jr., Measurement of Blood Pressure in Humans: A Scientific Statement From the American Heart Association, *Hypertension*, 73 (2019) e35-e66.
- [21] G. Stergiou, P. Palatini, R. Asmar, A. de la Sierra, M. Myers, A. Shennan, J. Wang, E. O'Brien, and G. Parati, Blood Pressure Measurement and Hypertension Diagnosis in the 2017 US Guidelines: First Things First, *Hypertension*, 71 (2018) 963-965.
- [22] P. E. Peppard, T. Young, M. Palta, and J. Skatrud, Prospective study of the association between sleep-disordered breathing and hypertension, *N. Engl. J. Med.*, 342 (2000) 1378-1384.
- [23] J. M. Marin, A. Agusti, I. Villar, M. Forner, D. Nieto, S. J. Carrizo, F. Barbe, E. Vicente, Y. Wei, F. J. Nieto, and S. Jelic, Association between treated and untreated obstructive sleep apnea and risk of hypertension, *JAMA*, 307 (2012) 2169-2176.
- [24] T. Dudenbostel and D. A. Calhoun, Resistant hypertension, obstructive sleep apnoea and aldosterone, *J. Hum. Hypertens.*, 26 (2012) 281-287.
- [25] Cardiorespiratory polygraphy Alice NightOne device. 2020.
Ref Type: Generic
- [26] Alpel HolCARD CR-07. 2020.
Ref Type: Generic
- [27] K. Bibbins-Domingo, D. C. Grossman, S. J. Curry, K. W. Davidson, J. W. Epling, Jr., F. A. Garcia, J. Herzstein, A. R. Kemper, A. H. Krist, A. E. Kurth, C. S. Landefeld, C. M. Mangione, W. R. Phillips, M. G. Phipps, M. P. Pignone, M. Silverstein, and C. W. Tseng, Screening for Obstructive Sleep Apnea in Adults: US Preventive Services Task Force Recommendation Statement, *JAMA*, 317 (2017) 407-414.

- [28] R. P. Pedrosa, L. F. Drager, C. C. Gonzaga, M. G. Sousa, L. K. de Paula, A. C. Amaro, C. Amodeo, L. A. Bortolotto, E. M. Krieger, T. D. Bradley, and G. Lorenzi-Filho, Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension, *Hypertension*, 58 (2011) 811-817.
- [29] G. T. O'Connor, B. Caffo, A. B. Newman, S. F. Quan, D. M. Rapoport, S. Redline, H. E. Resnick, J. Samet, and E. Shahar, Prospective study of sleep-disordered breathing and hypertension: the Sleep Heart Health Study, *Am. J. Respir. Crit Care Med.*, 179 (2009) 1159-1164.
- [30] P. Verdecchia, F. Angeli, C. Borgioni, R. Gattobigio, and G. Reboldi, Ambulatory blood pressure and cardiovascular outcome in relation to perceived sleep deprivation, *Hypertension*, 49 (2007) 777-783.
- [31] L. Palagini, R. M. Bruno, A. Gemignani, C. Baglioni, L. Ghiadoni, and D. Riemann, Sleep loss and hypertension: a systematic review, *Curr. Pharm. Des.*, 19 (2013) 2409-2419.
- [32] J. E. Gangwisch, A review of evidence for the link between sleep duration and hypertension, *Am. J. Hypertens.*, 27 (2014) 1235-1242.